Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
With new MiFID II regulations introduced in January, Hiddensee provides independent investment research mainly on forensic accounting and corporate governance. Analysts will search for inconsistencies and anomalies in the valuation of UK listed mid-cap and smaller companies and publish their reports to assist investors in deciding whether to buy or sell shares.
days to go:
Expired
investment:
£143,097
Pretty Athletic offers award-winning skincare solutions for athletic and active women. It makes high-performance, effective, and natural skin-care solutions for active women who sweat and experience exercise-related skincare problems. In 2018, the company's product Workout Glow was awarded the Pure Beauty Gold award for Best New Natural Face Product. It has now sold more than 15,000 units since its launch. Pretty Athletic has also collaborated with many brands such as Paola's Body Barre and Lululemon. With the proceeds, the company will intend to improve its Research & Development, Sales, and Packaging.
days to go:
Expired
investment:
£62,748
Capital Physio is one of the UK’s fastest growing providers of retail physiotherapy. Since inception in 2012, the group has opened 17 clinics as part of a highly scalable and growth driven business model.
days to go:
Expired
investment:
£6,210
For Good Causes turn Loyalty points into donations for charities, giving people a new way to give to causes closest to their hearts. Brands are given a while new CSR opportunity and charities are given much-needed funding. Research has shown their is over £7bn unused rewards in the UK, values which could be donated.
days to go:
Expired
investment:
£292,220
B-North intends to revolutionise the business lending industry, which is often outdated, impersonal and slow. The fintech company uses some of the most advanced cloud-based technology, coupled with face-to-face relationship teams to get the best lending solutions for borrowers and their businesses. The company is powered by a team with prior experience in starting and scaling challenger banks, and profitability is its focused goal. B-North has submitted the banking licence application, and the result is expected by 2020.
days to go:
Expired
investment:
£2,135,456
A FCA-authorised and regulated digital credit card on smartphones, for those with modern and busy lifestyles. Jaja aims to offer a fair and transparent banking service that gives consumers greater confidence, control and freedom over their finances. The company has tested their app and card with Visa and has partnered with Asda to offer online credit instantly.
Jaja's business model allows revenue to be generated via interest payments from revolving lines of credit. Two products will be offered to consumers; the Jaja Credit Card and Jaja Pay. Both will be suitable for B2B and B2C operations.
Investments will be used to launch a beta round for 5,000 users to build a community before the products are publicly released. In addition, Jaja intends to expand its customer service team and produce marketing campaigns for their business.
days to go:
Expired
investment:
£4,957,534
